Jefferies Group LLC Madrigal Pharmaceuticals, Inc. Transaction History

Jefferies Group LLC

  • $10.2 Billion
  • Q3 2022

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$78.35 - $105.02 $393,552 - $527,515
-5,023 Closed
0 $0
Q2 2021

Sep 21, 2023
BUY
$97.2 - $137.59 $2,235 - $3,164
23 Added 0.46%
5,023 $489,000
Q2 2021

Aug 16, 2021
BUY
$97.2 - $137.59 $2,235 - $3,164
23 Added 0.46%
5,023 $489,000
Q4 2020

Sep 21, 2023
BUY
$110.06 - $133.7 $550,300 - $668,500
5,000 New
5,000 $555,000
Q2 2020

Aug 14, 2020
BUY
$60.13 - $125.71 $210,455 - $439,985
3,500 Added 233.33%
5,000 $566,000
Q1 2020

May 15, 2020
SELL
$66.76 - $93.49 $656,117 - $918,819
-9,828 Reduced 86.76%
1,500 $100,000
Q4 2019

Feb 13, 2020
SELL
$84.28 - $118.5 $1.29 Million - $1.82 Million
-15,344 Reduced 57.53%
11,328 $1.03 Million
Q3 2019

Nov 13, 2019
SELL
$84.4 - $106.53 $1.68 Million - $2.13 Million
-19,949 Reduced 42.79%
26,672 $2.3 Million
Q2 2019

Aug 14, 2019
BUY
$91.13 - $142.5 $1.43 Million - $2.24 Million
15,685 Added 50.7%
46,621 $4.89 Million
Q1 2019

May 15, 2019
BUY
$103.48 - $143.84 $212,858 - $295,878
2,057 Added 7.12%
30,936 $3.88 Million
Q4 2018

Feb 14, 2019
BUY
$94.77 - $215.54 $2.3 Million - $5.23 Million
24,269 Added 526.44%
28,879 $3.26 Million
Q3 2018

Nov 14, 2018
BUY
$207.3 - $300.31 $955,653 - $1.38 Million
4,610 New
4,610 $987,000

Others Institutions Holding MDGL

# of Institutions
298
Shares Held
22M
Call Options Held
819K
Put Options Held
640K
View Full List

About MADRIGAL PHARMACEUTICALS, INC.

MDGL Quotes by TradingView
  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.32B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Jefferies Group LLC Portfolio

Follow Jefferies Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email